QR-Code

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience

<b>Background:</b> Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <b>Methods</b>: We retrospectively included all patients >1...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Maria Mazzitelli, Milo Gatti, Vincenzo Scaglione, Daniele Mengato, Marco Trevenzoli, Andrea Sattin, Federico Pea, Anna Maria Cattelan
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2022-10-01
Schriftenreihe:Antibiotics
Schlagworte:
dalbavancin
MRSA
spondylodiscitis
off-label
vertebral infections
TDM
Online-Zugang:https://www.mdpi.com/2079-6382/11/10/1377
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge